Why Choose Fractional Expertise?
Strategic Impact, Scalable Commitment.
Fractional working gives growing pharma and biotech companies the ability to:
​​
Access Senior Expertise Early.
Bring in experienced leadership without waiting for full-time hiring capacity.
Accelerate Decision-Making.
Gain expert input on partnering, fundraising, clinical strategy and regulatory pathways.
Stay Agile and Cost-Efficient.
Engage only when needed—no long-term overhead or recruitment delays.
Bridge Critical Gaps.
Cover key roles during transitions, expansions, maternity and paternity cover or before permanent hires are in place.
De-Risk Growth.
Leverage proven experience to make smarter, faster, and more informed choices.
About Me
Since starting in the industry in the late 90's I have had a passion for partnerships with an unwavering belief that the sum of the two parts should always be able to achieve more than either individually. I started my career on the vendor side creating client teams through to joining Roche in 2006 working in partnership with some of the largest CRO's and then in Roche Partnering for over a decade. I'm now working in partnership with organisations to help them achieve the goals they want. I'm a flexible resource to help support:
​
-
Chief Business Officer roles
-
Business Development activities
-
Alliance Management support and advice
-
Project Management
-
Vendor Management and vendor strategies
James Sabry, Executive Vice President, Chief Business Officer, BioMarin (previous head of Roche Partnering)
"Tim is a very capable, organized and creative business development professional. It was my pleasure to work with him for many years and witness this first hand on a number of transactions.”
Manish Tandon, Co-Founder and CFO Curadev Pharma
"I have known Tim for over 10 years. Throughout our collaboration with Roche, he continually demonstrated exceptional communication skills, strategic vision, and an unwavering commitment to the success of the collaboration. He truly believes that the most enduring innovation stems from thoughtful alignment and shared purpose."
John Quisel, JD, PhD
Chief Executive Officer, Disc Medicine
“Tim was a fantastic partner across the table as we built the agreements to license bitopertin from Roche and enable Disc Medicine to bring the program forward into a rare disease desperately in need of new therapies. He was able to negotiate fairly with us and manage the internal processes at Roche to create a true win-win collaboration.”
Contact
Tim Steven, MBA, BSc
KairoGen Ltd
Or Leave a Message Here
Stay Connected